The effect of comprehensive physiotherapy using the Gloreha Sinfonia robotic system on hand function in systemic sclerosis
| ISRCTN | ISRCTN23880621 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN23880621 |
| Sponsors | Czech Technical University in Prague, Institute of Rheumatology |
| Funder | České Vysoké Učení Technické v Praze |
- Submission date
- 26/07/2026
- Registration date
- 24/08/2026
- Last edited
- 24/08/2026
- Recruitment status
- No longer recruiting
- Overall study status
- Ongoing
- Condition category
- Musculoskeletal Diseases
Plain English summary of protocol
Background and study aims
Patients with systemic sclerosis, a rare autoimmune disease, suffer from connective tissue damage in the hands, among other areas. This condition affects patients in their daily activities, even with regular treatment. This study will focus on the use of the Gloreha Sinfonia robotic system as part of comprehensive hand rehabilitation over a period of 12 weeks.
Who can participate?
Patients with systemic sclerosis who have problems with hand and finger function and its mobility.
What does the study involve?
Participants will be randomly divided into two similarly sized groups, one of which will be the experimental group and the other the control group. Both groups will undergo full conventional physiotherapy, with the experimental group's therapy supplemented by exercises using the Gloreha Sinfonia robotic system. The examination should take 1 hour, during which the participants will undergo initial/final measurements, including filling out questionnaires, anthropometric and goniometric examinations, and measurements using the robotic device itself. After the examination, exercises lasting 2 hours (for the experimental group) and 1.5 hours (for the control group) will take place once a week (for both groups) for at least 12 weeks (again for both groups), starting the week after the examination. The follow-up examination will consist of a follow-up measurement, where the patient's current condition will be assessed after 1 month without robotic or conventional therapy.
What are the possible benefits and risks of participating?
The benefit should be increased range of motion and improved function in the hands and fingers. Physiotherapy may be accompanied by mild irritation of soft tissues during relaxation, or fatigue of the muscles being worked on. One of the risks may also be that the patient's condition does not improve.
Where is the study run from?
Czech Technical University in Prague - Faculty of Biomedical Engineering, and the Institute of Rheumatology (Czech Republic)
When is the study starting and how long is it expected to run for?
August 2026 to February 2027
Who is funding the study?
Czech Technical University in Prague (Czech Republic)
Who is the main contact?
Mr Daniel Štefl, stefldan@cvut.cz
Contact information
Principal investigator, Scientific
České Vysoké Učení Technické v Praze Fakulta Biomedicínského Inženýrství (ČVUT FBMI)
Sportovců 2311
Kladno
272 01
Czech Republic
| 0000-0002-9114-2172 | |
| Phone | +420 (0)776 058 038 |
| spirimaj@cvut.cz |
Public, Principal investigator
Na Hluboké cestě, 1477
Brandýs nad Labem - Stará Boleslav
250 01
Czech Republic
| 0009-0001-2254-3124 | |
| Phone | +420 (0)724 327 674 |
| stefldan@cvut.cz |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Randomized controlled trial |
| Masking | Open (masking not used) |
| Control | Active |
| Assignment | Parallel |
| Purpose | Device feasibility, Supportive care |
| Participant information sheet | 49993_PIS.pdf |
| Scientific title | The effect of Gloreha Sinfonia robotic system physiotherapy on hand function compared with standard physiotherapy in patients with systemic sclerosis: a randomized controlled trial |
| Study objectives | 1. To verify the benefits and feasibility of integrating the Gloreha Sinfonia robotic device into the concept of intensive hand rehabilitation for patients with systemic sclerosis (SSc) and to evaluate its impact on the recovery of motor functions and range of motion. 2. To evaluate the effectiveness of comprehensive physical therapy as supportive care complementing robotic therapy for overall improvement in hand function. 3. Analyze the long-term impact of this robot-assisted therapy on patients’ quality of life during follow-up. |
| Ethics approval(s) |
Approved 30/09/2025, Ethics committee of Institute of Rheumatology Prague (Na Slupi, 4, Praha, 128 00, Czech Republic; +420 (0)234 075 244; tomcik@revma.cz), ref: 14350/2025 |
| Health condition(s) or problem(s) studied | Systemic sclerosis (SSc) |
| Intervention | Pseudo-random number generation (PRNG): Eligible participants will be randomly assigned to either the experimental group or the control group using a computer-generated randomization sequence based on a pseudorandom number generator (PRNG). The randomization sequence will be generated prior to participant enrollment, and participants will be allocated in a 1:1 ratio. Experimental group: Participants will receive conventional physiotherapy supplemented by robotic-assisted therapy using the Gloreha Sinfonia device. The intervention will be performed once a week for at least 12 weeks, with each exercise session lasting 2 hours. Control group: Participants will receive conventional physiotherapy only. The intervention will be performed once a week for at least 12 weeks, with each exercise session lasting 1.5 hours. Assessments (both groups): All participants will undergo a baseline examination (1 hour) consisting of goniometric measurements, robotic device assessments, and standardized questionnaires validated for systemic sclerosis (SSc). The same set of measurements will be repeated at the end of the 12-week intervention period. A follow-up assessment will be conducted 4 weeks after the completion of the therapy to evaluate the sustainability of the outcomes during a period without active treatment. |
| Intervention type | Device |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Gloreha Sinfonia |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) |
|
| Completion date | 15/02/2027 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 75 Years |
| Sex | All |
| Target sample size at registration | 40 |
| Key inclusion criteria | 1. Ability to understand, sign, and date the Independent Ethics Committee-approved written Informed Consent form 2. Aged ≥ 18 and ≤ 75 years 3. Confirmed diagnosis of systemic sclerosis (SSc) verified by a rheumatologist 4. Established disease with no signs of acute exacerbation 5. Reduced range of active motion in the hand and finger joints, but retaining residual functional mobility (absence of total joint ankylosis or fixed muscle contractures) 6. Ability and willingness to adhere to the visit schedule, examination procedures, and full study protocol |
| Key exclusion criteria | 1. Active skin lesions, digital ulcers, or local infections on the target hand or fingers 2. Severe or fixed joint contractures preventing safe fitting or operation of the robotic glove 3. Symptomatic subcutaneous calcinosis in areas subject to pressure from the device 4. Severe Raynaud's phenomenon with critical digital ischemia 5. Recent surgery or trauma to the target hand or fingers within the last 6 months 6. Severe sensory loss or cognitive impairment preventing safe operation of the device 7. Concurrent treatment or rehabilitation that could interfere with the study outcomes 8. Any other medical condition that, in the opinion of the investigator, compromises patient safety or data validity |
| Date of first enrolment | 31/08/2026 |
| Date of final enrolment | 28/09/2026 |
Locations
Countries of recruitment
- Czech Republic
Study participating centres
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | 27/07/2026 | No | Yes |
Additional files
- 49993_PIS.pdf
- Participant information sheet
Editorial Notes
27/07/2026: Study's existence confirmed by the ethics committee of Institute of Rheumatology, Prague.